Johnson & Johnson rose 0.4% in early Friday trading. The company received approval from the US Food and Drug Administration: its RYBREVANT FasPro can be used in combination with lazertinib for first-line treatment of EGFR mutated non-small cell lung cancer to achieve 5-minute subcutaneous administration.

Johnson & Johnson rose 0.4% in early Friday trading. The company received approval from the US Food and Drug Administration: its RYBREVANT FasPro can be used in combination with lazertinib for first-line treatment of EGFR mutated non-small cell lung cancer to achieve 5-minute subcutaneous administration.